Omeros (OMER) Initiates Patient Enrollment for Second Phase 3 Trial of OMS302
Go back to Omeros (OMER) Initiates Patient Enrollment for Second Phase 3 Trial of OMS302| Omeros Corporation (NASDAQ: OMER) | Delayed: 19.27 +0.64 (3.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.63 | 52 Week High | $16.80 | |||
| Open | $18.64 | 52 Week Low | $7.20 | |||
| Day High | $19.58 | P/E | N/A | |||
| Day Low | $18.41 | EPS | $-1.64 | |||
| Volume | 2,582,610 | |||||
